Ebos Group Limited · NZX:EBO
Ebos — Investor Day (October 2015)
13 slides from Ebos's investor day presentation, Oct 13, 2015
Slide 1: Patrick Davies – CEO EBOS Group Ltd
For personal use only Patrick Davies – CEO EBOS Group Ltd 13 October 2015 1
Slide 2: Disclaimer
Disclaimer For personal use only The information in this presentation was prepared by EBOS Group Ltd with due care and attention. However, the information is supplied in summary form and is therefore not necessarily complete, and no representation is made as to the accuracy, completeness or reliabil
Slide 3: Introduction
Introduction For personal use only If you needed access to medicine in either New Zealand or Australia over the past year – whether through your local pharmacy, in a hospital, an aged care facility or even for your pet through a vet – it’s likely EBOS played a vital role in getting that medicine to
Slide 4: EBOS Group – Snapshot
EBOS Group – Snapshot For personal use only EBOS Group is the largest and most diversified Australasian marketer, wholesaler and distributor of healthcare, medical and pharmaceutical products. It is also a leading Australasian animal care products marketer and distributor. 1 # combined pharmacy and
Slide 5: EBOS Group Overview
EBOS Group Overview Trans-Tasman Healthcare and Animal Care portfolio For personal use only ~$2 billion 42 market capitalisation locations in Australia Dual listed on NZX and ASX and New Zealand $6.1 billion 2,400+ FY15 revenue employees Australia 78%, NZ 22% $196.7 million 38,000+ FY15 EBITDA custo
Slide 6: EBOS Group Overview – Market channels
EBOS Group Overview – Market channels For personal use only HEALTHCARE ANIMAL CARE Community Pharmacy Institutional Healthcare Contract Logistics Pet Care and Veterinary Pharmacy Wholesale Product Pharmacy Services Pharmacy Retail Retail Consumer Products Wholesale EBOS is the trusted partner to gov
Slide 7: Segment and Geographic earnings overview
Segment and Geographic earnings overview Earnings contribution weighted to Healthcare and Australian based For personal use only Gross Operating Revenue Net Revenue 22% Australia New Zealand 78% EBITDA 19% Australia New Zealand 81% 7
Slide 8: Strong Financial Results in FY15
Strong Financial Results in FY15 For personal use only +7.2% +14.2% constant constant currency currency +16.9% +17.2% constant currency 8
Slide 9: Cash Flow
Cash Flow EBOS has an excellent portfolio of strong cash generating businesses For personal use only • Focus on tight working capital NZ$m FY15 FY14 Var$ Var% management led to record Operating EBITDA 196.7 175.4 21.3 12.1% cash flow of $133.8m being generated Interest paid (21.9) (27.1) 5.2 19.2% i
Slide 10: Net Debt and Gearing
Net Debt and Gearing For personal use only 400 40% • Net Debt of $316.9m at June 2015. 350 35% 368 350 300 316 317 30% • Net Debt : EBITDA reduced to 1.6x at June 2015 Net debt (NZ$m) Gearing ratio 250 25% 26.7% 26.9% (1.8x at June 2014). 200 24.4% 23.2% 20% 150 15% • Reduction in the Gearing ratio
Slide 11: EBOS strategy
EBOS strategy For personal use only • Protect and grow our market leading positions in pharmacy in both New Zealand and Australia – across wholesale, consumer products and pharmacy retail • Pursue further growth in the institutional Continue disciplined focus on healthcare market appropriately price
Slide 12: Track record of delivering shareholder value
Track record of delivering shareholder value For personal use only Earnings Per Share (cents) Dividends Per Share (cents) * 80.0 50.0 47.0 70.8 70.0 45.0 41.0 62.8 40.0 60.0 53.6 34.0 35.0 32.5 46.8 31.0 31.5 50.0 45.4 41.8 41.1 39.5 30.0 37.6 25.0 40.0 23.0 32.5 31.7 25.0 21.5 22.5 22.5 30.0 20.0 1
Slide 13: Track record of delivering shareholder value
Track record of delivering shareholder value For personal use only Share Price (NZ$) 13.00 12.00 11.00 +159.6% 10.00 (excluding dividends) 9.00 8.00 7.00 6.00 +18.9% 10 year compound annual return 5.00 (including dividends) 4.00 3.00 30-Sep-05 30-Sep-06 30-Sep-07 30-Sep-08 30-Sep-09 30-Sep-10 30-Sep